Assessing The Role Of Bridging Therapy Prior To The CAR-T Administration
Latest Information Update: 13 Dec 2019
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Tisagenlecleucel (Primary) ; Antineoplastics; Bendamustine; Cyclophosphamide; Ibrutinib; Lenalidomide; Obinutuzumab; Rituximab
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
Most Recent Events
- 13 Dec 2019 New trial record
- 10 Dec 2019 Results, Assessing the role of bridging therapy (therapy given after T-cell apheresis but prior to CAR-T infusion) prior to the CAR-T administration, presented at the 61st Annual Meeting and Exposition of the American Society of Hematology